Filing Flows › Health Care › Lunai Bioworks (LNAI)
Lunai Bioworks (LNAI) earnings and revenue breakdown
Latest: Q4 FY26 · 10-K filed Oct 13, 2026 · Lunai Bioworks (LNAI) Q4 FY26 earnings results →
Lunai Bioworks made $31K in Q4 FY26. Operating margin n/m, net loss $2.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Oct 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $31K in Q4 FY26, up 48% from the previous quarter.
Operating costs exceeded revenue by $2.1M, an operating margin of -6888.6%. The quarter ended with a net loss of $2.0M, narrower than the previous quarter's $2.6M loss.
Operating cash flow was −$1.8M. Non-cash charges added back $30K of depreciation and amortization and $151K of share-based compensation.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 FY26 | 10-K | Oct 13, 2026 | $31K | — | n/m | −$2.0M | −$1.8M |
| Q3 FY26 | 10-Q | May 15, 2026 | $21K | — | n/m | −$2.6M | −$1.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Lunai Bioworks
As of June 30, 2026, Lunai Bioworks Inc. operated principally through two operating subsidiaries, Renovaro Biosciences and BioSymetrics; a third wholly owned subsidiary, Lunai Bioworks IP, Inc., holds the intellectual property acquired in the May 2026 Neurobridge acquisition, including the N2B intranasal drug delivery platform. BioSymetrics refers to BioSymetrics Inc. and its wholly owned subsidiary BioSymetrics Corp., which were acquired on April 8, 2025. During the quarter ended September 30, 2025, GEDi Cube B.V. ("GEDi Cube"), acquired on February 13, 2024, filed for bankruptcy and ceased operations. Following GEDi Cube's bankruptcy and subsequent deconsolidation, the Company continued pursuing its AI-driven precision medicine and biomarker discovery strategy through BioSymetrics, which had been acquired prior to the bankruptcy.
In its own words, from its 10-K, filed Oct 13, 2026.
Lunai Bioworks against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LNAI Lunai Bioworks | Q4 FY26 | $31K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Lunai Bioworks 10-K on SEC EDGAR · CIK 1527728 · Pharmaceutical Preparations
13F: who owns LNAI and who is buying
More on LNAI
History
Every quarter: Q4 FY26 results · Q3 FY26 results